OBJECTIVE: The authors have established a methodological approach to evaluate head and neck squamous cell carcinoma aiming at identifying and distinguishing high metabolic activity inside the lesion, combining in a single examination, functional, metabolic and morphological data simultaneously acquired by means of different non-dedicated positron emission tomography (PET)-computed tomography (CT) device. MATERIALS AND METHODS: The study population included 17 patients with head and neck squamous cell carcinoma submitted to a non-dedicated 18F-FDG-PET imaging at Department of Diagnostic Imaging of Hospital do Câncer, São Paulo, SP, Brazil. CT and 18F-FDG-PET images were simultaneously acquired in a non-dedicated device. The original data were transferred to an independent workstation by means of the Entegra 2 NT software to generate PET-CT imaging fusion. RESULTS: The findings were defined as positive in the presence of a well defined focal area of increased radiopharmaceutical uptake in regions not related with the normal biodistribution of the tracer. CONCLUSION: The fusion of simultaneously acquired images in a single examination (18F-FDG-PET and CT) has allowed the topographic-metabolic mapping of the lesion as well as the localization of high metabolic activity areas inside the tumor, indicating recidivation or metastasis and widening the array of alternatives for radiotherapy or surgical planning.

Keywords: Squamous cell carcinoma, Computed tomography, Positron emission tomography, Face

Primary ovarian carcinoma rarely metastasizes to the breast, and few cases are described in the literature. The authors report the case of a patient with ovarian carcinoma that developed breast metastasis eight years after the initial diagnosis, and present a literature review on this subject, emphasizing imaging findings.

Keywords: Ovarian carcinoma; Breast metastasis; Imaging findings.

OBJECTIVE: To correlate the results of ¹⁸F-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) performed with a specific protocol for assessment of breasts with histological/immunohistochemical findings in breast carcinoma patients. MATERIALS AND METHODS: Cross-sectional study with prospective data collection, where patients with biopsy-confirmed breast carcinomas were studied. The patients underwent PET/CT examination in prone position, with a specific protocol for assessment of breasts. PET/CT findings were compared with histological and immunohistochemical data. RESULTS: The authors identified 59 malignant breast lesions in 50 patients. The maximum diameter of the lesions ranged from 6 to 80 mm (mean: 32.2 mm). Invasive ductal carcinoma was the most common histological type (n = 47; 79.7%). At PET/CT, 53 (89.8%) of the lesions demonstrated anomalous concentrations of ¹⁸F-FDG, with maximum SUV ranging from 0.8 to 23.1 (mean: 5.5). A statistically significant association was observed between higher values of maximum SUV and histological type, histological grade, molecular subtype, tumor diameter, mitotic index and Ki-67 expression. CONCLUSION: PET/CT performed with specific protocol for assessment of breasts has demonstrated good sensitivity and was associated with relevant histological/immunohistochemical factors related to aggressiveness and prognosis of breast carcinomas.

Keywords: Breast cancer; PET/CT; Histology.

OBJECTIVE: To evaluate positron emission tomography/computed tomography (PET/CT) and conventional imaging tests for the detection of distant metastases in patients with locally advanced breast cancer. MATERIALS AND METHODS: We included 81 patients with breast cancer who had undergone ¹⁸F-fluorodeoxyglucose (FDG) PET/CT before treatment. Conventional imaging included the following: bone scintigraphy; chest X-ray (in 14.5%) or CT (in 85.5%); and abdominal ultrasound (in 10.8%), CT (in 87.8%), or magnetic resonance imaging (in 1.4%). Histopathology and clinical/imaging follow-up served as reference. RESULTS: Distant metastases were observed in nine patients (11.1%). On patient-based analysis, conventional imaging identified distant metastases in all 9 patients. In one patient, the initial ¹⁸F-FDG PET/CT failed to demonstrate bone metastases that was evident on bone scintigraphy. In two patients, the CT scan failed to show extra-axillary lymph node metastases that were identified on ¹⁸F-FDG PET/CT. There was no significant difference between ¹⁸F-FDG PET/CT and conventional imaging in terms of their sensitivity for the detection of distant metastases in patients with locally advanced breast cancer. CONCLUSION: This study showed that ¹⁸F-FDG PET/CT and conventional imaging with CT scans had similar sensitivity for the diagnosis of distant metastases in patients with locally advanced breast cancer. ¹⁸F-FDG PET/CT can add information about extra-axillary lymph node involvements.

Keywords: Breast neoplasms; Positron-emission tomography; ¹⁸F-fluorodeoxyglucose.

OBJECTIVE: To compare ⁶⁸Ga-DOTA-DPhe1,Tyr3-octreotate (⁶⁸Ga-DOTATATE) positron-emission tomography/computed tomography (PET/CT) findings with those of conventional ¹¹¹In-octreotide scintigraphy in patients with neuroendocrine tumors (NETs). MATERIALS AND METHODS: This was a single-center prospective study including 41 patients (25 males; mean age, 55.4 years) with biopsy-proven NETs who underwent whole-body ¹¹¹In-octreotide scintigraphy and whole-body ⁶⁸Ga-DOTATATE PET/CT. The patients had been referred for tumor staging (34.1%), tumor restaging (61.0%), or response evaluation (4.9%). Images were compared in a patient-by-patient analysis to identify additional lesions, and we attempted to determine the impact that discordant findings had on treatment planning. RESULTS: Compared with ¹¹¹In-octreotide scintigraphy, ⁶⁸Ga-DOTATATE PET/CT revealed more lesions, the additional lesions typically being in the liver or bowel. Changes in management owing to the additional information provided by ⁶⁸Ga-DOTATATE PET/CT occurred in five patients (12.2%), including intermodal changes in three (7.3%) and intramodal changes in two (4.9%). In addition, ⁶⁸Ga-DOTATATE PET/CT yielded incidental findings unrelated to the primary NET in three patients (7.3%): Hürthle cell carcinoma of the thyroid, bowel non-Hodgkin lymphoma, and a suspicious breast lesion. CONCLUSION: We conclude that ⁶⁸Ga-DOTATATE PET/CT is superior to conventional ¹¹¹In-octreotide scintigraphy for the management of NETs because of its ability to determine the extent of the disease more accurately, which, in some cases, translates to changes in the treatment plan.

Keywords: Carcinoma, neuroendocrine/diagnostic imaging; Positron-emission tomography/methods; Tomography, X-ray computed/methods; Radionuclide imaging/methods.